U.S. Markets close in 1 hr 40 mins
  • S&P 500

    3,691.18
    +24.46 (+0.67%)
     
  • Dow 30

    30,165.76
    +196.24 (+0.65%)
     
  • Nasdaq

    12,438.53
    +61.35 (+0.50%)
     
  • Russell 2000

    1,881.60
    +32.89 (+1.78%)
     
  • Crude Oil

    46.20
    +0.56 (+1.23%)
     
  • Gold

    1,839.60
    -1.50 (-0.08%)
     
  • Silver

    24.27
    +0.14 (+0.57%)
     
  • EUR/USD

    1.2145
    -0.0004 (-0.0364%)
     
  • 10-Yr Bond

    0.9680
    +0.0480 (+5.22%)
     
  • Vix

    20.84
    -0.44 (-2.07%)
     
  • GBP/USD

    1.3454
    +0.0001 (+0.0094%)
     
  • USD/JPY

    104.1230
    +0.2630 (+0.2532%)
     
  • BTC-USD

    19,058.09
    -199.50 (-1.04%)
     
  • CMC Crypto 200

    373.54
    -5.70 (-1.50%)
     
  • FTSE 100

    6,550.23
    +59.96 (+0.92%)
     
  • Nikkei 225

    26,751.24
    -58.13 (-0.22%)
     

Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

Cidara Therapeutics, Inc.
·1 min read

SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in two upcoming conferences: the Stifel 2020 Virtual Healthcare Conference and 3rd Annual Evercore ISI HealthCONx Conference.

Stifel 2020 Virtual Health Conference

Date:

Tuesday, November 17, 2020

Time:

2:00 PM Eastern Time

Format:

Presentation

A live audio webcast of the presentation will be available in the Investors section on the Company’s website at www.cidara.com.

3rd Annual Evercore ISI HealthCONx Conference

Date:

Wednesday, December 2, 2020

Time:

11:20 AM Eastern Time

Format:

Panel Discussion - No Fungus Among Us: Addressing an Important Fungal Need

About Cidara Therapeutics
Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

MEDIA CONTACT:
Karen O’Shea, Ph.D.
LifeSci Communications
(929) 469-3860
koshea@lifescicomms.com